Endocrinology and Metabolism

Review Article

Thyroid
Management of Low-Risk Papillary Thyroid Cancer: Nicole M. Iñiguez-Ariza, Juan P. Brito; Endocrinol Metab. 2018;33(2):185-194. Published online June 21, 2018; DOI: https://doi.org/10.3803/EnM.2018.33.2.185

6,396 View
104 Download
34 Web of Science
34 Crossref

The incidence of thyroid cancer has increased, mainly due to the incidental finding of low-risk papillary thyroid cancers (PTC). These malignancies grow slowly, and are unlikely to cause morbidity and mortality. New understanding about the prognosis of tumor features has led to reclassification of many tumors within the low-risk thyroid category, and to the development of a new one “very low-risk tumors.” Alternative less aggressive approaches to therapy are now available including active surveillance and minimally invasive interventions. In this narrative review, we have summarized the available evidence for the management of low-risk PTC.

Citations

Citations to this article as recorded by

Risk of malignancy in Thy3 thyroid nodules
Emad Mofid Nassif Rezkallah, Ragai Sobhi Hanna, Wael Magdy Elsaify
Endocrine Regulations.2024; 58(1): 19. CrossRef
Adequacy of clinical guideline recommendations for patients with low-risk cancer managed with monitoring: systematic review
Kiana K. Collins, Claire Friedemann Smith, Tori Ford, Nia Roberts, Brian D. Nicholson, Jason L. Oke
Journal of Clinical Epidemiology.2024; 169: 111280. CrossRef
Integrated metabolic and genetic analysis reveals distinct features of human differentiated thyroid cancer
Eduardo Cararo Lopes, Akshada Sawant, Dirk Moore, Hua Ke, Fuqian Shi, Saurabh Laddha, Ying Chen, Anchal Sharma, Jake Naumann, Jessie Yanxiang Guo, Maria Gomez, Maria Ibrahim, Tracey L. Smith, Gregory M. Riedlinger, Edmund C. Lattime, Stanley Trooskin, Shr
Clinical and Translational Medicine.2023;[Epub] CrossRef
Clinical management of low-risk papillary thyroid microcarcinoma
Chie MASAKI, Kiminori SUGINO, Koichi ITO
Minerva Endocrinology.2022;[Epub] CrossRef
The circ_FAM53B-miR-183-5p-CCDC6 axis modulates the malignant behaviors of papillary thyroid carcinoma cells
Chong Zhang, Huxia Gu, Dingrong Liu, Fuyun Tong, Huijie Wei, Dan Zhou, Jing Fang, Xiaolu Dai, Haibo Tian
Molecular and Cellular Biochemistry.2022; 477(11): 2627. CrossRef
An Appraisal and Update of Fluorodeoxyglucose and Non-Fluorodeoxyglucose-PET Tracers in Thyroid and Non–Thyroid Endocrine Neoplasms
Aadil Adnan, Shobhana Raju, Rakesh Kumar, Sandip Basu
PET Clinics.2022; 17(3): 343. CrossRef
A Narrative Review of Preventive Central Lymph Node Dissection in Patients With Papillary Thyroid Cancer - A Necessity or an Excess
David D. Dolidze, Alexey V. Shabunin, Robert B. Mumladze, Arshak V. Vardanyan, Serghei D. Covantsev, Alexander M. Shulutko, Vasiliy I. Semikov, Khalid M. Isaev, Airazat M. Kazaryan
Frontiers in Oncology.2022;[Epub] CrossRef
Ethanol Ablation as a Treatment in a Low-Risk Follicular Thyroid Cancer: A Case Report
Juan Pesantez, Carla Lituma, Carla Valencia, Jose Prieto, Marco Cazorla
Cureus.2022;[Epub] CrossRef
The new T3b category has clinical significance? SEER‐based study
Jingzhe Xiang, Zhihong Wang, Wei Sun, Hao Zhang
Clinical Endocrinology.2021; 94(3): 449. CrossRef
Efficacy and Safety of Thermal Ablation for Solitary T1bN0M0 Papillary Thyroid Carcinoma: A Multicenter Study
Xiao-Jing Cao, Juan Liu, Ya-Lin Zhu, Lu Qi, Geng Liu, Hong-Ling Wang, Zhong-Hua Wang, Ying Zhou, Jun-Feng He, Jian-Qin Guo, Li-Li Shi, Mei Jian, Aini Shataer, Guo-Zhen Yan, Zhen-Long Zhao, Ying Wei, Li-Li Peng, Yan Li, Ying Che, Shu-Rong Wang, Ming-An Yu
The Journal of Clinical Endocrinology & Metabolism.2021; 106(2): e573. CrossRef
A Clinical Audit of Hemithyroidectomy for Differentiated Thyroid Cancer—Experience from a Tertiary Cancer Center
Nithyanand Chidambaranathan, Shivakumar Thiagarajan, Nandini Menon, Adhara Chakraborthy, Richa Vaish, Devendra Chaukar
Indian Journal of Surgery.2021; 83(6): 1444. CrossRef
Pros and cons of hemi‐thyroidectomy for low‐risk differentiated thyroid cancer
Alexander J. Papachristos, Anthony Glover, Mark S. Sywak, Stan B. Sidhu
ANZ Journal of Surgery.2021; 91(9): 1704. CrossRef
Lactate Dehydrogenase A as a Potential New Biomarker for Thyroid Cancer
Eun Jeong Ban, Daham Kim, Jin Kyong Kim, Sang-Wook Kang, Jandee Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kunhong Kim
Endocrinology and Metabolism.2021; 36(1): 96. CrossRef
Taraxasterol inhibits TGF-β1-induced epithelial-to-mesenchymal transition in papillary thyroid cancer cells through regulating the Wnt/β-catenin signaling
J Zhu, X Li, S Zhang, J Liu, X Yao, Q Zhao, B Kou, P Han, X Wang, Y Bai, Z Zheng, C Xu
Human & Experimental Toxicology.2021; 40(12_suppl): S87. CrossRef
Is Delayed Papillary Thyroid Cancer Surgery Associated with Higher Mortality Risk?
Eddy P. Lincango Naranjo, Juan P. Brito
Clinical Thyroidology.2021; 33(9): 400. CrossRef
MicroRNA-99a-3p/GRP94 axis affects metastatic progression of human papillary thyroid carcinoma by regulating ITGA2 expression and localization
Yun Gao, Yi Pan, Tingting Wang, Ying Yao, Wenbo Yuan, Xue Zhu, Ke Wang
Acta Biochimica et Biophysica Sinica.2021; 53(12): 1650. CrossRef
Microscopic Extrathyroidal Extension Results in Increased Rate of Tumor Recurrence and Is an Independent Predictor of Patient’s Outcome in Middle Eastern Papillary Thyroid Carcinoma
Sandeep Kumar Parvathareddy, Abdul K. Siraj, Zeeshan Qadri, Felisa DeVera, Khawar Siddiqui, Saif S. Al-Sobhi, Fouad Al-Dayel, Khawla S. Al-Kuraya
Frontiers in Oncology.2021;[Epub] CrossRef
New paradigms in the treatment of low-risk thyroid cancer
Firas Baidoun, Anas M. Saad, Omar Abdel-Rahman
Expert Review of Endocrinology & Metabolism.2020; 15(4): 251. CrossRef
The Impact of Transcription Factor Prospero Homeobox 1 on the Regulation of Thyroid Cancer Malignancy
Magdalena Rudzińska, Barbara Czarnocka
International Journal of Molecular Sciences.2020; 21(9): 3220. CrossRef
Modified risk stratification based on cervical lymph node metastases following lobectomy for papillary thyroid carcinoma
Eyun Song, Jonghwa Ahn, Dong Eun Song, Won Woong Kim, Min Ji Jeon, Tae‐Yon Sung, Tae Yong Kim, Ki Wook Chung, Won Bae Kim, Young Kee Shong, Suck Joon Hong, Yu‐Mi Lee, Won Gu Kim
Clinical Endocrinology.2020; 92(4): 358. CrossRef
Clinicopathological significance of the single nucleotide polymorphism, rs2853669 within the TERT promoter in papillary thyroid carcinoma
Tatsuya Hirokawa, Yuu Arimasu, Tomohiro Chiba, Masachika Fujiwara, Hiroshi Kamma
Pathology International.2020; 70(4): 217. CrossRef
Diagnostic accuracy and ability to reduce unnecessary FNAC: A comparison between four Thyroid Imaging Reporting Data System (TI-RADS) versions
Lingsze Tan, Ying Sern Tan, Suzet Tan
Clinical Imaging.2020; 65: 133. CrossRef
Amino Acid Transporters as Potential Therapeutic Targets in Thyroid Cancer
Keisuke Enomoto, Muneki Hotomi
Endocrinology and Metabolism.2020; 35(2): 227. CrossRef
FDG PET/CT versus somatostatin receptor PET/CT in TENIS syndrome: a systematic review and meta-analysis
Felipe Alves Mourato, Maria Amorim Almeida, Ana Emília Teixeira Brito, Aline Lopes Garcia Leal, Paulo Almeida Filho, Elba Etchebehere
Clinical and Translational Imaging.2020; 8(5): 365. CrossRef
Factors Associated with Health Behaviors in Thyroid Cancer Survivors
Junghyun Yoon, Boyoung Park
Journal of Cancer Prevention.2020; 25(3): 173. CrossRef
Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening
Luc H.J. Sondorp, Vivian M.L. Ogundipe, Andries H. Groen, Wendy Kelder, Annelies Kemper, Thera P. Links, Robert P. Coppes, Schelto Kruijff
Cancers.2020; 12(11): 3212. CrossRef
Hemithyroidectomy for Thyroid Cancer: A Review
Noor Addasi, Abbey Fingeret, Whitney Goldner
Medicina.2020; 56(11): 586. CrossRef
Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis
Jonghwa Ahn, Meihua Jin, Eyun Song, Min Ji Jeon, Tae Yong Kim, Jin-Sook Ryu, Won Bae Kim, Young Kee Shong, Ji Min Han, Won Gu Kim
Endocrinology and Metabolism.2020; 35(4): 830. CrossRef
Clinical Significance of Gross Invasion of Strap Muscles in Patients With 1- to 4-cm-Sized Papillary Thyroid Carcinoma Undergoing Lobectomy
Eyun Song, Won Woong Kim, Min Ji Jeon, Tae-Yon Sung, Dong Eun Song, Tae Yong Kim, Ki Wook Chung, Won Bae Kim, Young Kee Shong, Suck Joon Hong, Yu-Mi Lee, Won Gu Kim
Annals of Surgical Oncology.2019; 26(13): 4466. CrossRef
Lobectomy Is Feasible for 1–4 cm Papillary Thyroid Carcinomas: A 10-Year Propensity Score Matched-Pair Analysis on Recurrence
Eyun Song, Minkyu Han, Hye-Seon Oh, Won Woong Kim, Min Ji Jeon, Yu-Mi Lee, Tae Yong Kim, Ki Wook Chung, Won Bae Kim, Young Kee Shong, Suck Joon Hong, Tae-Yon Sung, Won Gu Kim
Thyroid.2019; 29(1): 64. CrossRef
Laser and radiofrequency ablations for benign and malignant thyroid tumors
Giovanni Mauri, Nicolò Gennaro, Min Kyoung Lee, Jung Hwan Baek
International Journal of Hyperthermia.2019; 36(2): 13. CrossRef
US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population
Hyun Kyung Lim, Se Jin Cho, Jung Hwan Baek, Kang Dae Lee, Chang Woo Son, Jung Min Son, Seon Mi Baek
Korean Journal of Radiology.2019; 20(12): 1653. CrossRef
Utility of Early Postoperative Unstimulated Thyroglobulin in Influencing Decision Making in Patients with Papillary Thyroid Carcinoma
Alexandria D. McDow, Cynthia M. Shumway, Susan C. Pitt, David F. Schneider, Rebecca S. Sippel, Kristin L. Long
Annals of Surgical Oncology.2019; 26(12): 4002. CrossRef
Extent of Surgery for Low-Risk Differentiated Thyroid Cancer
Alexandria D. McDow, Susan C. Pitt
Surgical Clinics of North America.2019; 99(4): 599. CrossRef

Original Articles

Percutaneous Ethanol Injection in Autonomous Functioning Thyroid Nodules and Complex Cysts: Five Years' Experience.: Seong Jin Lee, Jung Hee Han, Ha Young Kim, Jong Chul Won, Sang Wook Kim, Ho Kyu Lee, Il Min Ahn; J Korean Endocr Soc. 2002;17(1):57-68. Published online February 1, 2002

1,037 View
17 Download

Abstract PDF: BACKGROUND
Percutaneous ethanol injection therapy (PEI) performed with ultrasonography guidance has recently been used in cases of autonomous functioning thyroid nodules (AFTN) and benign complex cysts. We performed this study to analyze the effects of PEI on AFTN and benign complex cysts. METHEODS: From September 1995 to September 2000, we performed PEI on 456 outpatients (47 men and 409 women, mean age 42.4+/-11.8 years) with AFTN or benign complex cysts. All cases were subjected to fine needle aspirations (FNA) by ultrasonography-guidance if necessary. FNA was performed at least twice with results of colloid nodule in cases of complex cysts. For AFTN, cases with FNA results of follicular neoplasm were also included. After PEI on AFTN, patients were classified into three response groups: complete response as judged by our new criteria (CR, normalization of TSH and free T4, disappearance of hot nodule on thyroid scan) along with the old criteria of previous studies (normalization of TSH and free T4, recovery of suppressed extranodular tissue on thyroid scan), partial response (PR, normalized free T4 but suppressed TSH, persistent hot nodule despite recovery in suppressed extranodular tissue) and no response (no change of hot nodule). Complex cysts were classified into three groups in accordance with volume reduction after PEI: complete response (CR, above 90% of volume reduction), partial response (PR, 50~89%) and no response (below 50%). RESULTS: Overall pre-treatment volumes were 15.3+/-12.1 mL and post-treatment volumes were 2.8+/-2.9 mL, with 66.4+/-19.9% of volume reductions in AFTN and complex cysts. Volume reductions were 71.5+/-18.0% in AFTN, and 66.1+/-15.0% in complex cysts. In 24 cases of AFTN, responses satisfying the previous criteria were 14 (58.3%) of CR, 6 (25.0%) of PR, and 4 (16.7%) of no response. However, by the new criteria there were 1 (4.2%) of CR, 10 (41.6%) of PR, and 13 (54.2%) of no response. In 432 cases of complex cysts, CR was observed in 82 (19.0%), PR in 261 (60.4%) and no response in 89 (20.6%). The volume reductions in complex cysts with pre-treatment volume larger than 15 mL were higher than those of groups with smaller volumes (p<0.001). Pre-treatment volumes were not correlated with post-treatment volumes, nor with volume reductions. Volume reductions were not correlated with the amounts of injected ethanol. Mild and transient complications were observed in 41 cases (9.0%) during PEI, consisting of transient neck pain (n=36, 7.9%), transient unilateral vocal cord palsy (n=3, 0.7%), intracavitary hemorrhage (n=1, 0.2%), and transient hypotension (n=1, 0.2%). CONCLUSION: Our data suggest that the efficacy of PEI on AFTN is temporary and does not usually induce long-term complete remissions. In complex cysts, however, PEI may have potential as an additive treatment modality to thyroid hormone suppressive therapy

Effectiveness of Percutaneous Ethanol Injection in Benign Cold Thyroid Nodules: Five Years' Experience.: Seong Jin Lee, Jung Hee Han, Ha Young Kim, Jong Chul Won, Sang Wook Kim, Ho Kyu Lee, Il Min Ahn; J Korean Endocr Soc. 2001;16(2):210-220. Published online April 1, 2001

1,036 View
17 Download

Abstract PDF: BACKGROUND
Percutaneous ethanol injection therapy (PEI) which is performed with the guidance of ultrasonography has recently been used in patient who had benign cold thyroid nodules. We performed this study to analyze the long-term effects of PEI on benign cold thyroid nodules. METHOD: From September 1995 to September 2000, we treated 198 outpatients (12 men and 186 women, who had a mean age of 40.8 years, with a range of 15-71) who had benign cold thyroid nodules at the Asan Medical Center. The PEI was performed on 141 patients who had solitary nodules (SN) and on 57 patients who had prominent nodules or Questionable or typing error? multiple nodules (MN). All patients had fine needle aspirations (FNAs) at least twice which resulted in a diagnosis of the presence of a colloid nodule. Thyroid hormone was given to all patients along with TSH measurements. The thyroid hormone dose was titrated to correspond to TSH level of a low normal range. These patients were followed up for mean period of 37.6 months (range 18-60). Patients who were treated with PEI were classified into three groups according to their volume reduction: a complete response (CR, which was above 90% in volume reduction), a partial response (PR, which was a 50-89%) reduction and No Response (which was below 50% or an increased size) groups. RESULTS: The overall pre-treatment volumes of the nodules were 15.7+/-19.8 mL. The overall post-treatment volumes were 2.4+/-2.6 mL and consisted of volume reductions of 70.1+/-17.1%. The results of PEI for all of the patients were: a complete reduction (CR) in 34 cases (17.2%), a partial reduction (PR) in 142 cases (71.7%) and No Response in 22 patients (11.1%). In 141 patients in the SN group, in which there was a mean follow-up duration of 36.7+/-11.2 months, the volume reductions were 68.3+/-18.8%. CR was observed in 20 patients (14.2%), PR in 103 (73.0%) and No Response in 18 (12.8%). In twenty-two of the SN patients (22/141, 15.6%) we were able to discontinue the thyroid hormone suppressive therapy because those nodules had markedly decreased in volume after PEI without any further increase of nodule size during the follow-up period. In 57 patients in the MN group, over a mean follow-up durations of 37.1+/-11.4 months, the volume reductions were 74.3+/-12.1%. CR was observed in 14 patients (24.6%), PR in 39 (68.4%) and No Response occurred in 4 (7.0%). During the follow-up period after PEI, further volume reductions were observed for 36 months after thyroid hormone suppressive therapy in the Response Group. Differences in volume reductions between the SN and MN groups were not statistically significant but the volume reductions in patients who had a pre-treatment volume larger than 15 mL were higher than those in the smaller group (p<0.001). In the cases of the SN and MN groups, volume reductions did not correlate with either the amount of injected ethanol or the pre-treatment volumes, but the pre-treatment volumes correlated with post-treatment volumes in the patients who had SN (p<0.001, r=0.411) and MN (p<0.001, r=0.729). We observed mild, but transient complications in 32 patients (16.2%) during PEI which included a transient neck pain (n=27, 13.6%), a transient unilateral vocal cord palsy (n=4, 2.0%), and an abscess formation (n=1, 0.5%) which was cured. CONCLUSION: These results suggest that PEI is a feasible adjunctive therapy to use in thyroid hormone suppressive therapy for benign cold thyroid nodules

First
Prev
Page of 1
Next
Last

Search